Visceral Adiposity (central fat accumulation) Increase in Limb Fat after Stopping Nucleoside Analogue Therapy Is Not Associated with Decreased Visceral Fat and Has Different Risk Factors - 12/09/05 Visceral Fat Mass and the Risk of Insulin Resistance and Cardiovascular Disease - 12/09/05 Comparison of Rosiglitazone and Metformin for Treatment of HIV-related Lipodystrophy - 9/19/05 Impact of Rosiglitazone Treatment on the Bioavailability of Antiretroviral Drugs in HIV Patients - 9/19/05 Serono Completes Clinical Milestone in Phase III Trial of Human Growth Hormone (Serostim) for HIV-associated Adipose Redistribution Syndrome (HARS) - 6/17/05 Fat Redistribution Predicts Cardiac Risk in Women with HIV - 5/27/05
Lipodystrophy / Morphologic Changes (body shape changes)
• Fat Loss (lipoatrophy) • Fat Accumulation (lipotrophy) • Buffalo Hump (BH) • Cardiovascular Disease • Cosmetic Procedures • Facial Implants • Growth Hormone • HIV Wasting • Hormone Therapies • Steroids • Visceral Adiposity
Metabolic Complications
• Cardiovascular Disease • Cholesterol / Triglycerides • Diabetes • Dyslipidemias • Glucose Metabolism / Insulin Resistance • Gynecomastia • Hyperlactatemia • Hyperlipidemia • Infective Endocarditis • Myocardial Infarction (MI)
